Roche sees a slight dip in Q1 as biosimilars keep biting into blockbuster oncology trio's sales
With Roche facing a fast decline for its oncology blockbuster trio amid a biosimilar onslaught, the drug giant is looking anywhere it can for a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
